An observational study in Endometriosis, sponsored by University of Edinburgh. Recruiting at 1 site in United Kingdom. Open to female participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2026-05-27.
Sponsored by University of Edinburgh · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 25 studies in Endometriosis with a site in United Kingdom — 10 open to participants now, 11 under way, none of them phase 3. Endometriosis · United Kingdom.
Among the 25 studies in Endometriosis with a site in United Kingdom, this one is the 10th largest by planned enrollment of the 12 observational ones that give a count, is one of 2 that started in 2026, is one of 12 observational ones, reaches primary completion later than 5 of the 10 other live ones, and was the 24th registered.
924 studies on the registry are indexed under Endometriosis; 268 are open to participants now.
Browse Endometriosis studies →10 of the 25 studies in Endometriosis with a site in United Kingdom are open now. Recruiting first, the newest first:
University of Edinburgh · Sites in United Kingdom
Ages 16+ · Women only
University of Edinburgh · Sites in United Kingdom
Ages 16+ · Women only
University of Oxford · Sites in United Kingdom
Ages 18–50 · Women only
University of Edinburgh · Sites in United Kingdom
Ages 18+ · Women only · Healthy volunteers
University Hospitals of North Midlands NHS Trust · Sites in United Kingdom
Ages 18–50 · Women only
A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →
Of the 180 Endometriosis studies recruiting now, 53 (29%) set no upper age limit and 125 (69%) stop at 75 or younger; 18 take children under 18; 39 take healthy volunteers.
This study: 18 Years to 60 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
25 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 2 started in 2026.
This study's planned enrollment of 30 is below the median of 132 across 351 observational studies indexed under Endometriosis.
Median enrollment 50 across the 13 interventional studies, 100 across the 12 observational. Of the 11 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
7 of 25 have an industry lead sponsor. The 10 most frequent:
University of Edinburgh is the lead sponsor of 403 studies on the registry; 64 are open to participants now.
University of Edinburgh has 6 studies filed under Endometriosis — fewer than ten, so there is no comparison to draw.
4 of the studies in Endometriosis with a site in United Kingdom that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07603960University of EdinburghWhole-Body Cryotherapy as a Non-Pharmacological Treatment to Reduce Chronic Pelvic Pain and Improve Quality of Life in People With Endometriosis | 2026-11 |
| NCT06852248University Hospitals of North Midlands NHS TrustUreteric Identification Using Indocyanine Green Dye Versus Conventional Ureteric Stenting to Reduce Post-operative Pain and Surgical Morbidity During Endometriosis Surgery | 2027-03 |
| NCT07523997University of EdinburghImaging of Endometriosis With Total-body PET-CT (PET-Endo) | 2027-04-01 |
| NCT07260669Gesynta Pharma ABA Phase 2 Trial to Investigate Efficacy and Safety of Vipoglanstat in Women With Endometriosis | 2027-06 |
Add all 4 to your calendar (.ics) → With an account.
Among the 25 studies in Endometriosis with a site in United Kingdom, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Endometriosis is a disease that affects 1 in 10 women and is associated with debilitating pain and infertility. Endometriosis is where cells similar to those lining the womb (the 'endometrium') grow elsewhere in the body, forming 'lesions'. Most commonly the lesions grow on the lining of the pelvic cavity, called 'peritoneal' endometriosis. Lesions can also grow on the ovary, this is called 'ovarian' endometriosis, or form nodules, called 'deep' endometriosis.
At present the only way to confidently identify endometriosis is through surgery, this exposes patient to the risks of surgery and contributes to the diagnostic delay associated with endometriosis.
PET/CT is a specialist scan that is commonly used to identify cancers which cannot be seen on other types of scans. PET/CT uses a 'tracer', a substance given into a vein which then temporarily accumulates in areas of disease.
This project will determine if a new specialist scan, total body PET/CT, and novel tracers that were developed for other conditions can be used to identify some of the key pathways in endometriosis: bleeding and scarring. Being able to identify these processes in endometriosis lesions and being able to track how they change over time would improve our understanding of endometriosis. The investigators also want to know if these pathways are different between superficial, deep and ovarian endometriosis, and what the impact is of the hormones related to the menstrual cycle.
In this study up to 30 people who have suspected endometriosis and are already due to undergo diagnostic surgery will be asked to undergo two total-body PET/CT scans in Edinburgh, one at one visit and one another visit. Participants will also have a PET/MRI scan at visit. Participants will have a different tracer at each visit. The investigators will then compare the scan findings with their subsequent surgical findings.
This will be an observational cohort study using a prospectively recruited cohorts for both cross-sectional and longitudinal comparison across the spectrum of endometriosis subtypes.
Up to 30 participants with a clinical/radiological diagnosis of likely endometriosis and due to undergo confirmatory laparoscopy in the subsequent four months will be recruited.
Data collected at baseline includes demographics, clinical history including previous imaging. Participants will complete the WERF EPHect questionnaire
Participants will attend two visits for imaging. They will undergo advanced imaging by total-body positron emission tomography and computed tomography (PET/CT), followed by PET/MRI for anatomical reconciliation of lesions and additional information about tracer dynamics. At one visit 68Ga-FAPI will be administered, and at the other 18F-GP1. IV buscopan will be given prior to the PET/MRI.
Following completion of imaging studies, participants will be invited to complete an online acceptability questionnaire, and complete and optional qualitative interview about their experience.
Subsequent surgical findings and associated histopathology will be correlated with tracer uptake
30 patients in NHS Lothian with clinically diagnosed endometriosis due to undergo confirmatory laparoscopy in the subsequent four months will be recruited. All subjects recruited for the study will be able to withdraw from the study at any time. The patients will be referred to the study by their treating physicians to investigate clinically diagnosed endometriosis. We will not recruit or enroll healthy volunteers in this study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Women/those assigned female at birth (aged ≥18 years) with chronic pelvic pain and a clinical/radiological diagnosis of likely endometriosis and due to undergo confirmatory laparoscopy in the subsequent four months.
Diagnostic Test: PET/CT · Diagnostic Test: PET/MRI · Drug: Buscopan 20 MG/ML Injectable Solution
Hybrid positron emission tomography and computed tomography will be performed after intravenous administration of the 68Ga-FAPI or the 18F-GP1 radiotracer and images centred on the pelvis. Attenuation-correction CT will be performed before acquisition of PET data
Hybrid PET/MRI will be performed on a 3T scanner with T1 mapping immediately after the PET/CT with images acquired centred on the pelvis after injection of buscopan
Drug page: Butylscopolammonium BromideStudies of Butylscopolammonium BromideButylscopolammonium Bromide pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.
IV injection prior to PET/MRI
Also known as: 20mg
In vivo uptake of 18F-GP1 and 68Ga-FAPI in endometriosis
Tracer uptake will be quantified by determining standardized uptake values (SUVs) and tissue to background ratio (TBR) in areas of increased uptake within the abdomen. This will correlated with surgical findings, specifically presence and location of endometriosis lesions.
Time frame: within 3 months post surgery
Non-invasive in vivo imaging-based characterisation of thrombosis and fibrosis characterisation in superficial, ovarian and deep endometriosis lesions
Tracer uptake will be quantified by determining standardized uptake values (SUVs) and tissue to background ratio (TBR) in areas of increased uptake within the abdomen. The relative values for the two separate tracers GP1 (activated platelets) and FAPI (fibrosis) will be correlated with the macroscopic appearance of lesions of differing subtypes at surgery.
Time frame: within 3 months post surgery
Acceptability of PET imaging for characterisation of endometriosis
Bespoke acceptability questionnaire will be administered following surgery. Acceptability of the overall study and specific aspects will be rated on a 5 point Likert scale, with free text options for further detail. Data will summarised despitative, with thematic analysis of free text where able. Additional acceptability data will be derived from qualitative interviews of a purposive sample of participants and analysed thematically.
Time frame: within 3 months post surgery
Plan to share: Undecided — Requests for anonymised data sharing will be considered on a case by case basis by the trial management team with appropriate data sharing contracts in place
No publications or documents are linked to this record.
Started Apr 2026 (actual). Primary completion is estimated for Apr 2027, 11 months after the start.
Of 158 non-industry observational studies under Endometriosis, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 48. This study's planned 11 months is below that.
Counting every sponsor, half of 185 studies reached it within 30 months; a quarter within 14 and three quarters within 47.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.